Aspergillosis: Clinical Trials

10 trials for Aspergillosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 terminated, 1 withdrawn. 10 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 110Completed 8, Terminated 1, Withdrawn 1
Phase 22Terminated 1, Withdrawn 1

Follow Aspergillosis: new trials by email Literature Review of Aspergillosis trials Research Report on Aspergillosis

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma
Voriconazole Inhalation Powder, Placebo - Asthma
Phase 1CompletedTFF Pharmaceuticals, Inc.172020-11-152021-11-18
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
Voriconazole inhaled, oral voriconazole - Allergic Bronchopulmonary Aspergillosis
Phase 1CompletedZambon SpA582020-02-112021-11-15
Single Ascending Dose and Multiple Ascending Dose Study of Voriconazole Inhalation Powder in Healthy Adult Subjects
Voriconazole Inhalation Powder, Placebo - Healthy
Phase 1CompletedTFF Pharmaceuticals, Inc.652019-11-222021-05-06
Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study)
Amphotericin B Liposomal 50 MG, Placebo - Invasive Pulmonary Aspergillosis
Phase 1CompletedFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal132019-10-182023-06-15
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
PC945 - single doses, Placebo - single doses, PC945 - repeat doses - Aspergillosis
Phase 1CompletedPulmocide Ltd292017-10-232018-05-01
Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients
F901318, Caspofungin - Pulmonary Aspergillosis - Invasive, Acute Myeloid Leukemia
Phase 1 / Phase 2WithdrawnF2G Ltd2017-04-202018-02-15
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
Vorico Injection 200mg(Voriconazole), Vfend®(Voriconazole) IV 200mg - Aspergillus Infections, Candida Infections
Phase 1CompletedChong Kun Dang Pharmaceutical242015-09-012020-03-18
Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients
Placebo, QBW251 - Cystic Fibrosis
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals1532012-07-312020-12-30
Voriconazole to Prevent Systemic Fungal Infections in Children
Voriconazole - Aspergillosis, Candidiasis
Phase 1CompletedNational Cancer Institute (NCI)482000-06-012008-03-04
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
FK463 - Fever, Mycoses
Phase 1CompletedNational Cancer Institute (NCI)1201998-10-012008-03-04

Narrower conditions

Mycoses (5)  ·  Asthma (3)  ·  Candidiasis (3)  ·  Aspergillosis, Allergic Bronchopulmonary (2)  ·  Fungemia (2)  ·  Invasive Pulmonary Aspergillosis (2)  ·  Pulmonary Aspergillosis (2)  ·  Respiratory Aspiration (2)  ·  Cystic Fibrosis (1)  ·  Fever (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Neutropenia (1)

Broader conditions

Bacterial Infections and Mycoses (10)  ·  Infections (10)  ·  Lung Diseases (7)  ·  Respiratory Tract Diseases (7)  ·  Lung Diseases, Fungal (6)  ·  Mycoses (5)  ·  Hypersensitivity (4)  ·  Hypersensitivity, Immediate (4)  ·  Immune System Diseases (4)  ·  Invasive Fungal Infections (4)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Pulmonary Aspergillosis (4)  ·  Respiratory Hypersensitivity (4)

Interventions

Voriconazole (3)  ·  Amphotericin B (1)  ·  Caspofungin (1)  ·  Micafungin (1)  ·  icenticaftor (1)  ·  liposomal amphotericin B (1)  ·  olorofim (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  TFF Pharmaceuticals, Inc. (2)  ·  Chong Kun Dang Pharmaceutical (1)  ·  F2G Ltd (1)  ·  Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (1)  ·  Novartis Pharmaceuticals (1)  ·  Pulmocide Ltd (1)  ·  Zambon SpA (1)

Countries

United Kingdom (3)  ·  United States (3)  ·  Australia (1)  ·  Belgium (1)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Ireland (1)  ·  Romania (1)  ·  South Korea (1)  ·  Spain (1)

Top investigators

Dale Christensen, PhD (2)  ·  Muna Albayaty, MBChB, FFPM, MSc (1)  ·  Oliver Cornely, PhD, MD (1)  ·  Sonsoles Sancho (1)  ·  Sukh Dave Singh, Prof, MD, (1)

Results publications

PMID 32468741, PMID 33293212, PMID 39918069

NIH funding

2015 (1), 2019 (1)